GlassScriptPhysician profile
Vani Velkuru
NPI 1811174428
$9,658.91
in general payments reported to CMS, 2019-2025
27 companies · $2,569 in 2025
The $2,569 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,340 · 2020: $397 · 2021: $603 · 2022: $1,141 · 2023: $1,222 · 2024: $2,387 · 2025: $2,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,141 · Education: $36.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,140.87 |
| Education | $36.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,560.20 | 2019-2025 | Enbrel, Otezla, Otezla |
| Janssen Biotech, INC. | $1,729.92 | 2019-2025 | Tremfya |
| Ucb, INC. | $1,054.18 | 2019-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $719.80 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $709.35 | 2019-2025 | |
| Glaxosmithkline, LLC. | $616.16 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $371.32 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $284.23 | 2022-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.20 | 2022-2025 | Ofev, Jascayd |
| Pfizer INC. | $207.04 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $152.84 | 2019 | |
| Horizon Therapeutics Plc | $148.31 | 2021-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $143.06 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $123.72 | 2020-2024 | Acthar |
| Celgene Corporation | $70.83 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $67.70 | 2025 | Octagam Immune Globulin (Human) |
| Lilly USA, LLC | $64.83 | 2025 | Taltz |
| Genentech USA, INC. | $62.79 | 2025 | Actemra |
| Sobi, INC | $58.53 | 2024 | |
| Aurinia Pharma U.S., INC. | $53.38 | 2023-2024 | Lupkynis |
| Fresenius Kabi USA, LLC | $43.25 | 2024 | Tyenne, Idacio |
| Genzyme Corporation | $32.74 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $30.51 | 2024 | Tremfya |
| Ultragenyx Pharmaceutical INC. | $24.58 | 2021 | |
| Oxford Immunotec USA INC | $22.95 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.95 | 2022 | |
| Celltrion USA INC. | $17.54 | 2023 | Yuflyma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vani Velkuru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.